MAPT and Alzheimer disease: PET and CSF protein analysis were used to detect the contents of the Aβ and tau proteins in the cerebrospinal fluid of patients to determine whether they are at risk of AD (Mantzavinos and Alexiou, 2017; Scheltens et al., 2021).